Literature DB >> 12084334

Neoadjuvant hormone therapy before radical prostatectomy does not improve disease-specific survival.

M S Steiner1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 12084334     DOI： 10.1007/s11934-000-0028-y

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN： 1527-2737            Impact factor:   2.862


× No keyword cloud information.
  7 in total

1.  Neoadjuvant Hormonal Therapy Prior to Radical Prostatectomy.

Authors: 
Journal:  Mol Urol       Date:  1999

Review 2.  Review of peptide growth factors in benign prostatic hyperplasia and urological malignancy.

Authors:  M S Steiner
Journal:  J Urol       Date:  1995-04       Impact factor: 7.450

3.  Neoadjuvant Hormone Therapy Before Radical Prostatectomy: Update on the Memorial Sloan-Kettering Cancer Center Trials.

Authors: 
Journal:  Mol Urol       Date:  1999

4.  Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group.

Authors:  M S Soloway; R Sharifi; Z Wajsman; D McLeod; D P Wood; A Puras-Baez
Journal:  J Urol       Date:  1995-08       Impact factor: 7.450

5.  Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group.

Authors:  M V Pilepich; J M Krall; M al-Sarraf; M J John; R L Doggett; W T Sause; C A Lawton; R A Abrams; M Rotman; P Rubin
Journal:  Urology       Date:  1995-04       Impact factor: 2.649

Review 6.  Use of neoadjuvant androgen deprivation therapy in clinically localized prostate cancer.

Authors:  W R Fair; A G Aprikian; D Cohen; P Sogani; V Reuter
Journal:  Clin Invest Med       Date:  1993-12       Impact factor: 0.825

7.  Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer.

Authors:  M E Gleave; S L Goldenberg; E C Jones; N Bruchovsky; L D Sullivan
Journal:  J Urol       Date:  1996-01       Impact factor: 7.450
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.